Abstract
Delivery of cancer chemotherapy directly to the cancer cell has great appeal. Previous studies using adenoviral transfer of the herpes simplex virus thymidine kinase (HSV-tk) gene followed by ganciclovir (GCV) in an ascites model of breast cancer was successful in reducing tumor burden and prolonging life. However, increasing the viral dose resulted in increased toxicity and host mortality emphasizing the need for an improved therapeutic ratio. To test the hypothesis that enhancement of HSV-tk gene expression would lead to increased sensitivity to GCV and improved bystander effect, we created breast cancer cells expressing HSV-tk under the control of the inducible tetracycline promoter. Using this system, we could inducibly increase gene expression and biochemical activation of HSV-tk. These increased levels of HSV-tk decreased the IC50 to GCV nearly 50-fold. However, the bystander effect was not enhanced by increasing HSV-tk gene expression. We conclude that increased HSV-tk gene expression improves sensitivity to CCV. However, additional measures, such as increased gap junction communication, will likely be needed to enhance the bystander effect and the therapeutic efficacy of this strategy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, Moore JO: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6: 1368–1376, 1988
Arnold K: High-dose chemo and breast cancer: early results spark debate. J Natl Cancer Inst 91: 992–994, 1999
Yee D, McGuire SE, Brunner N, Kozelsky TW, Allred DC, Chen SH, Woo SLC: Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum Gene Ther 7: 1251–1257, 1996
Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46: 5276–5281, 1986
Elshami AA, Cook JW, Amin KM, Choi H, Park JY, Coonrod L, Sun J, Molnar-Kimber K, Wilson JM, Kaiser LR, Albelda SM: The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapy in vitro and in vivo. Cancer Gene Ther 4: 213–221, 1997
Gossen M, Feundlieb S, Bender G, Muller G, HillenW, Bujard H: Transcriptional activation by tetracyclines in mammalian cells. Science 268: 1766–1769, 1995
Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685, 1970
Liu QY, Summers WC: Site-directed mutagenesis of a nucleotide-binding domain in HSV-l thymidine kinase: effects on catalytic activity. Virology 163: 638–642, 1988
Ives DH, Wang SM: Deoxycytidine kinase from calf thymus. Methods Enzymol 51: 337–345, 1978
Twentyman PR, Luscombe M: A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 56: 279–285, 1987
Dilber MS, Abedi MR, Christensson B, Bjorkstrand B, Kidder GM, Naus CCG, Gahrton G, Smith CIE: Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res 57: 1523–1528, 1997
Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, Amin KM, Kaiser LR, Albelda SM: Gap junctions play a role in the ‘bystander effect’ of the herpes simplex virus thymidine kinase ganciclovir system in vitro. Gene Ther 3: 85–92, 1996
Freeman SM, Ramesh R, Shastri M, Munshi A, Jensen AK, Marrogi AJ: The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells. Cancer Lett 92: 167–174, 1995
Ishii-Morita H, Agbaria R, Mullen CA, Hirano H, Koeplin DA, Ram Z, Oldfield EH, Johns DO, Blaese RM: Mechanism of ‘bystander effect’ killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther 4: 244–251, 1997
Vrionis FD, Wu JK, Qi P, Waltzman M, Cherington V, Spray DC: The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions. Gene Ther 4: 577–585, 1997
Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H: Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 93: 1831–1835, 1996
Pitts JD: Cancer gene therapy: a bystander effect using the cap junctional pathway. Mol Carcin 11: 127–130, 1994
Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D: Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 90: 7024–7028, 1993
Hirschi KK, Xu CE, Tsukdmoto T, Sager R: Gap junction genes Cx26 and Cx43 individually suppress the cancer phenotype of human mammary carcinoma cells and restore differentiation potential. Cell Growth Differ 7: 861–870, 1996
McMasters RA, Saylors RL, Jones KE, Hendrix ME, Moyer MP, Drake RR: Lack of bystander killing in herpes simplex virus thymidine kinase-transduced colon cell lines due to deficient connexin43 gap junction formation. Hum Gene Ther 9: 2253–2261, 1998
Rights and permissions
About this article
Cite this article
Patil, R., Chavez, J.B. & Yee, D. Inducible expression of herpes simplex virus thymidine kinase increases sensitivity to ganciclovir but does not enhance bystander effect in breast cancer cells. Breast Cancer Res Treat 62, 109–115 (2000). https://doi.org/10.1023/A:1006443720829
Issue Date:
DOI: https://doi.org/10.1023/A:1006443720829